Trick or Trade- Prohost Biotech - Exclusive Biotech Research

Category: Trick or Trade

Could Precision Biosciences Gene Editing Firm Become the Only Company to Cure the Life-Threatening HBV Resistant Infection

Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness Precision BioSciences ( DTIL ) is an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated...

February 15, 2024

Travere Therapeutics Fourth Quarter and Full Year 2023 Financial Results

Travere Therapeutics in the NEWS Yesterday, Feb. 15, 2024, Travere Therapeutics, Inc. ( TVTX ) reported its fourth quarter and full year 2023 financial results and provided a corporate update. Eric Dube, Ph.D., president and chief executive officer of...

February 16, 2024

BioCardia Inc Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial

BioCardia Inc in the NEWS BioCardia, Inc. ( BCDA ) , a biotechnology company focused on advancing late-stage cell therapy interventions for cardiovascular disorders, today announced positive interim results from the Phase III randomized controlled trial of its CardiAMP® autologous cell...

March 4, 2024

Selecting New Small Biotech Firms for Investment

During a discussion with colleagues about the best way to select small and new biotechnology firms for investment purposes, we started our answer by stating that selecting small and new biotechnology firms for investments is extremely challenging. As a matter...

March 20, 2024

Illumina Stock Price Will Rebound With or Without This News

Illumina in the NEWS On March 21, 2024, we learned that the EU antitrust regulators suffered a blow as an adviser to Europe's top court said that they exceeded their powers when they blocked U.S. Illumina's ( ILMN ) $7.1 billion...

March 22, 2024

BioStem Technologies' Press Release and Conference Call Offered Encouraging News

BioStem Technologies Inc From Jason Matuszewski, CEO of BioStem Technologies ( BSEM ) , who stated, “BioStem had an outstanding fourth quarter. Revenue reached $11.5 million, nearly 14 times higher than revenue of roughly $0.8 million for last year’s comparable...

April 2, 2024

Serious is the Impact of Bad Circumstances

The Impact of Bad Circumstances Since early year 2024, in every Prohost Letter we have posted, we added a memo stating that we have decided to be careful not to underestimate the bad circumstances under which the world is currently...

August 6, 2024

Merck Discontinues Two Late-Stage Keytruda Trials and Other Important Information

Merck Updates Merck ( MRK ) provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630, stating that it discontinued Phase 3 KEYNOTE-867 trial evaluating KEYTRUDA in combination with stereotactic body radiotherapy ( SBRT ) for the treatment of patients...

August 29, 2024

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024